Sort
53,477 grants matching “addiction”
Nrf2 Activation for Addiction-Free Treatment of Neuropathic Pain
$3,224,916Peter M Grace · University Of Tx Md Anderson Can Ctr · RF1 · FY2019 · NS
Genetic Analysis of Attention Deficit Hyperactivity Disorder
$3,217,699Paul Liu · National Human Genome Research Institute · ZIA · FY2020 · HG
Conte Center: Understanding Latent Cause Inference in Health and Illness
$3,210,120Yael Niv · Princeton University · P50 · FY2025 · MH
Selective Control of Synaptically-Connected Circuit Elements by Interluminescence
$3,208,469Ute H Hochgeschwender · Central Michigan University · R01 · FY2021 · NS
University of Michigan (UM) HEAL Initiative National K12 Clinical Pain Career Development Program (UM-HCPDP)
$3,202,476David A Williams · University Of Michigan At Ann Arbor · K12 · FY2022 · NS
Dysfunctional lipid metabolism and peroxidation in chronic pain and neurodegeneration
$3,199,356Christopher Ramsden · National Institute On Aging · ZIA · FY2025 · AG
Multimodal preclinical imaging studies of decisional determinants of drug vs non-drug choice
$3,197,496Charles Bradberry · National Institute On Drug Abuse · ZIA · FY2023 · DA
HEAL: Probe/Drug Lead Production
$3,197,055Matthew Hall · National Center For Advancing Translational Sciences · ZIA · FY2019 · TR
Psychometric Reliability and Validity for Behavioral Metrics of Osteoarthritic Pain in Horses
$3,196,061Kyle D Allen · University Of Florida · R01 · FY2024 · AR
Associative learning, decision-making, and addiction
$3,194,213Geoffrey Schoenbaum · National Institute On Drug Abuse · ZIA · FY2019 · DA
Basic and Translational Research Center for Reducing Health Disparities
$3,189,400Jesus Alexander Angulo · Hunter College · G12 · FY2014 · MD
Naltrexone Transdermal Patch - An Accessible, Patient-Focused Option to Treat OUD Relapse
$3,187,507Andrew Gardiner · Libero Pharma Limited · UG3 · FY2022 · DA
1-Year Sustained Release Naltrexone Implant for the prevention of relapse to opioid dependence
$3,184,237Frank J Martin · Delpor, Inc. · UG3 · FY2020 · DA
Integrative genetics of behavior with high throughput technologies
$3,183,826David Goldman · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2015 · AA
Arylepoxamides: A new class of potent, safer analgesics
$3,182,170Ying-Xian Pan · Sloan-Kettering Inst Can Research · UG3 · FY2020 · DA
Deep sequencing studies for cannabis and stimulant dependence
$3,178,807Kirk C. Wilhelmsen · Univ Of North Carolina Chapel Hill · R01 · FY2014 · DA
Peripherally-restricted non-addictive cannabinoids for cancer pain treatment
$3,174,343Igor Spigelman · University Of California Los Angeles · UG3 · FY2023 · NS
Evaluation of psilocybin as an adjunctive treatment for opioid use disorder in methadone-maintained patients who continue to use illicit opioids
$3,172,763Michael Parks Bogenschutz · New York University School Of Medicine · UG3 · FY2025 · DA
Integrative genetics of behavior with high throughput technologies
$3,169,828David Goldman · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2014 · AA
Naltrexone Transdermal Patch - An Accessible, Patient-Focused Option to Treat OUD Relapse
$3,163,508Andrew Gardiner · Libero Pharma Limited · UG3 · FY2023 · DA
Supporting Treatment Access and Recovery for Co-Occurring Opioid Use and Mental Health Disorders (STAR-COD)
$3,155,199David A Smelson · Univ Of Massachusetts Med Sch Worcester · R01 · FY2021 · MH
Deep sequencing studies for cannabis and stimulant dependence
$3,150,292Kirk C. Wilhelmsen · Univ Of North Carolina Chapel Hill · R01 · FY2013 · DA
Biased Mu-Opioid Receptor Analgesics to Prevent Overdose and Opioid Use Disorders
$3,146,950Lawrence C Kuo · Mebias Discovery, Inc. · UH3 · FY2020 · DA
CLINICAL CENTER FOR MONITORING HEALTH IN WTC RESPONDERS
$3,146,697Iris Greenberg Udasin · Univ Of Med/Dent Nj-R W Johnson Med Sch · U10 · FY2010 · OH
Mouse models of stress disorders and addiction
$3,139,828Andrew Holmes · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2024 · AA